Search

Your search keyword '"Cha, Eugene K."' showing total 505 results

Search Constraints

Start Over You searched for: Author "Cha, Eugene K." Remove constraint Author: "Cha, Eugene K."
505 results on '"Cha, Eugene K."'

Search Results

2. Natural History and Genomic Landscape of Chemotherapy-Resistant Muscle-Invasive Bladder Cancer

3. Changes in the Perioperative Management and Outcomes of Patients With Upper Tract Urothelial Carcinoma Undergoing Radical Nephroureterectomy at Memorial Sloan Kettering Cancer Center: Over 20 Years of Experience

4. Long-term Outcomes of Local and Metastatic Small Cell Carcinoma of the Urinary Bladder and Genomic Analysis of Patients Treated With Neoadjuvant Chemotherapy

5. PD34-08 A PROSPECTIVE RANDOMIZED PHASE 3 TRIAL EVALUATING BENEFITS OF PERISTOMAL MESH PLACEMENT AT THE TIME OF RADICAL CYSTECTOMY AND ILEAL CONDUIT FORMATION

7. Association of patients’ sex with treatment outcomes after intravesical bacillus Calmette–Guérin immunotherapy for T1G3/HG bladder cancer

9. Natural history, response to systemic therapy, and genomic landscape of plasmacytoid urothelial carcinoma

10. Clinical and Genomic Characterization of Bladder Carcinomas With Glandular Phenotype

13. Correction: Natural history, response to systemic therapy, and genomic landscape of plasmacytoid urothelial carcinoma

15. Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets

16. Neoadjuvant nivolumab (N) + ipilimumab (I) in cisplatin-ineligible patients with upper tract urothelial cancer (UTUC): Updated results.

21. Association of Biochemically Verified Post-Diagnosis Smoking and Nonmuscle-Invasive Bladder Cancer Recurrence Risk

22. Supplementary Methods from Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial Carcinoma

23. Table S1-S7 from Small-Cell Carcinomas of the Bladder and Lung Are Characterized by a Convergent but Distinct Pathogenesis

24. Table S2 from Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial Carcinoma

25. Figure S1 from Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial Carcinoma

26. Figure S5 from Small-Cell Carcinomas of the Bladder and Lung Are Characterized by a Convergent but Distinct Pathogenesis

27. Supplemental Data (Figures and Tables) from DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial Carcinoma

28. Multicenter Phase II Clinical Trial of Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy for Patients With High-Grade Upper Tract Urothelial Carcinoma

29. Neoadjuvant nivolumab (N) + ipilimumab (I) in cisplatin-ineligible patients with upper tract urothelial cancer (UTUC).

36. Impact of Histological Variants on Clinical Outcomes of Patients with Upper Urinary Tract Urothelial Carcinoma

37. Prognostic Value of Extranodal Extension and Other Lymph Node Parameters in Patients With Upper Tract Urothelial Carcinoma

39. Phase I study of intravesical anti-CD40 agonist antibody 2141-V11 for non-muscle invasive bladder cancer unresponsive to Bacillus Calmette-Guerin (BCG) therapy.

40. Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial

41. Feasibility of a geriatric comanagement (GERICO) pilot program for patients 75 and older undergoing radical cystectomy

42. Defining hereditary upper tract urothelial carcinoma: Implications for genetic testing and clinical management.

43. Neoadjuvant nivolumab (N) +/- ipilimumab (I) in cisplatin-ineligible patients (pts) with muscle-invasive bladder cancer (MIBC).

Catalog

Books, media, physical & digital resources